- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Exosens SAS (EXENS)
Exosens SAS stock price live, this page displays EPA EXENS stock exchange data. View the EXENS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Exosens SAS real time stock price chart below.
What Is the Exosens SAS Stock Price Today?
The Exosens SAS stock price today is 40.70.
What Is the Stock Symbol for Exosens SAS?
The stock symbol for Exosens SAS is ""EXENS.""
What Stock Exchange Does Exosens SAS Trade On?
Exosens SAS is listed and trades on the Paris stock exchange.
Is Exosens SAS a Good Stock to Buy?
Determining whether Exosens SAS—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EXENS quote. (ISIN: FR001400Q9V2)
What Is the Exosens SAS Stock Price Today?
The Exosens SAS stock price today is 40.70.
What Is the Stock Symbol for Exosens SAS?
The stock symbol for Exosens SAS is ""EXENS.""
What Stock Exchange Does Exosens SAS Trade On?
Exosens SAS is listed and trades on the Paris stock exchange.
Is Exosens SAS a Good Stock to Buy?
Determining whether Exosens SAS—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EXENS quote. (ISIN: FR001400Q9V2)
40.70
+0.60(+1.50%)
Closed·
Fair Value
An estimate of a Exosens's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
39.95
41.20
52 wk Range
16.84
46.60
EXENS Scorecard
Full Analysis
Net income is expected to grow this year
EXENS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Exosens's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
39.9541.20
52 wk Range
16.8446.60
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.25%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.25%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EXENS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Exosens's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
42.57
Upside
+4.60%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
- Exosens SAS receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Mimbeau Holding receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Exosens SAS receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Exosens SAS receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Mimbeau Holding receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Exosens SAS receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Mimbeau Holding receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Mimbeau Holding receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Exosens SAS Company Profile
Exosens engages in the development, manufacture, and sale of electro-optical technologies in the fields of amplification, and detection and imaging in France, rest of Europe, North America, Asia, Oceania, Africa, and internationally. It offers image intensifier tubes; ultra violet, short and long wave infrared, visible - near infrared, and mid wave infrared cameras, as well as enhanced vision equipment; ion and electron, scintillation, and single photon detection products; x-ray components, neutronic imaging products, and image intensifiers for scientific applications; and gamma and neutron detectors, and mineral insulated extensions. The company also provides power tubes and microwave devices; and methane airborne detection solutions. It operates under the Photonis, Xenics, Telops, and El-Mul brand names. The company serves defense and surveillance, industrial research and control, life science and environment, and nuclear markets. The company was founded in 1937 and is based in Mérignac, France. Exosens operates as a subsidiary of HLD Europe S.C.A.
Exosens SAS Earnings Call Summary for Q4/2024
- Exosens reported 35% YoY revenue growth to €394M in Q4 2024, with stock surging 15.47% pre-market
- Net profit increased 66% YoY to €30.7M; company announced first-ever dividend of €0.1 per share
- EBITDA reached €118.5M with 30.1% margin; leverage ratio improved to 1.2x from 3.3x
- Management projects high-teens revenue growth and low 20s EBITDA growth for 2025
- Company expanding capacity in US and Europe, pursuing selective M&A to enhance technological capabilities
Last Updated: 03/03/2025, 10:10
Read Full TranscriptCompare EXENS to Peers and Sector
Metrics to compare | EXENS | Sector Sector - Average of metrics from a broad group of related Industrials sector companies | Relationship RelationshipEXENSPeersSector | |
|---|---|---|---|---|
P/E Ratio | 36.5x | 33.7x | 12.7x | |
PEG Ratio | 0.03 | 0.09 | 0.03 | |
Price/Book | 4.7x | 3.9x | 1.4x | |
Price / LTM Sales | 4.7x | 1.7x | 1.3x | |
Upside (Analyst Target) | 7.6% | 11.3% | 14.3% | |
Fair Value Upside | Unlock | −5.3% | 5.3% | Unlock |
Analyst Ratings
6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 42.57
(+4.60% Upside)
Earnings
Latest Release
Jul 31, 2025
EPS / Forecast
0.27 / --
Revenue / Forecast
112.26M / 119.50M
People Also Watch
FAQ
What Stock Exchange Does Exosens Trade On?
Exosens is listed and trades on the Paris Stock Exchange stock exchange.
What Is the Stock Symbol for Exosens?
The stock symbol for Exosens is "EXENS."
What Is the Exosens Market Cap?
As of today, Exosens market cap is 2.05B.
What Is Exosens's Earnings Per Share (TTM)?
The Exosens EPS (TTM) is 1.10.
When Is the Next Exosens Earnings Date?
Exosens will release its next earnings report on 26 Oct 2025.
From a Technical Analysis Perspective, Is EXENS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Exosens Stock Split?
Exosens has split 0 times.
How Many Employees Does Exosens Have?
Exosens has 1400 employees.
What is the current trading status of Exosens (EXENS)?
As of 25 Aug 2025, Exosens (EXENS) is trading at a price of 40.70, with a previous close of 40.10. The stock has fluctuated within a day range of 39.95 to 41.20, while its 52-week range spans from 16.84 to 46.60.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.